Open AccessEfficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials
Author(s) -
Sung Gyu Lee,
Long Bin Jeng,
Faouzi Saliba,
Arvinder S. Soin,
Wei Chen Lee,
Paolo De Simone,
Frederik Nevens,
Kyung Suk Suh,
Lutz Fischer,
Dong Jin Joo,
John J. Fung,
JaeWon Joh,
Toshimi Kaido,
David Grant,
Matthias Meier,
Barbara Rauer,
C. Sips,
Shuhei Kaneko,
Gary Levy
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000003394
Subject(s) - medicine , renal function , everolimus , tacrolimus , randomization , gastroenterology , urology , hepatocellular carcinoma , confidence interval , kidney disease , liver transplantation , regimen , randomized controlled trial , milan criteria , transplantation
Data from 2 randomized liver transplant trials (N = 772; H2304 [deceased donor, n = 488], H2307 [living donor, n = 284]) were pooled to further evaluate the efficacy and safety of everolimus with reduced tacrolimus (EVR + rTAC) versus standard tacrolimus (sTAC) regimen at month 24.